Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$28.12
-1.83 (-6.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $100.8M · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
45.4x
↑EV/EBITDA
16.5x
↑ROE
4.7%
↑Gross Margin
42.5%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.7%
FCF CAGR
+3.8%
FCF margin
20.1%
FCF / Net income
1.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $639.4M · net income $104.8M · FCF $128.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $639.4M | $639.4M | $497.0M | $766.8M | $716.7M |
| Net Income | $104.8M | $104.8M | $38.6M | $173.6M | $161.5M |
| EBITDA | $183.6M | $183.6M | $107.0M | $273.7M | $253.1M |
| EPS | 0.87 | 0.87 | 0.32 | 1.73 | 1.79 |
| Gross Margin | 42.5% | 42.5% | 35.2% | 47.2% | 44.1% |
| Operating Margin | 17.8% | 17.8% | 6.0% | 27.3% | 25.4% |
| Net Margin | 16.4% | 16.4% | 7.8% | 22.6% | 22.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 |
| Current Ratio | 16.57 | 16.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $128.4M | $128.4M | $100.8M | $82.3M | $114.9M |
| Returns | |||||
| ROE | 4.7% | 4.7% | 1.8% | 8.0% | 18.4% |
| Valuation | |||||
| P/E | 45.35 | 45.35 | 77.41 | 25.67 | — |
| EV/EBITDA | 16.45 | 16.45 | 26.19 | 14.54 | — |
| P/B | 1.53 | 1.53 | 1.39 | 2.05 | — |
| Growth & Yield | |||||
| Revenue Growth | 28.6% | 28.6% | -35.2% | 7.0% | — |
| EPS Growth | 171.9% | 171.9% | -81.5% | -3.1% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
42.1%
EPS terminal req.
$2.50
Spread vs growth
129.8%
5Y implied EPS CAGR
28.3%
EPS terminal req.
$3.02
Spread vs growth
143.6%
10Y implied EPS CAGR
18.8%
EPS terminal req.
$4.86
Spread vs growth
153.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.7%
Start / end P/E
106.8x → 32.3x
EPS bridge
0.32 → 0.87
Residual
-119.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.